Mosaic ImmunoEngineering Inc. (CPMV)
| Market Cap | 3.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.25M |
| Shares Out | 7.24M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32 |
| Open | 0.499 |
| Previous Close | 0.550 |
| Day's Range | 0.499 - 0.550 |
| 52-Week Range | 0.302 - 1.045 |
| Beta | -1.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CPMV
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California. [Read more]
Financial Performance
Financial StatementsNews
Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101
- Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities - - MIE-101 has demonstrated potent, dur...
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform
- Research grants provided by the National Cancer Institute will support continued development and study of cowpea mosaic virus (CPMV) as an immuno-oncology candidate - - One grant will focus on optim...
Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Plat-form
- Research grants provided by the National Cancer Institute will support continued development and study of cowpea mosaic virus (CPMV) as an immuno-oncology candidate - - One grant will focus on optim...
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth College The license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for ...
Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression...
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
- Nanoparticle technology shown to be effective in transforming immunologically "cold" tumors to "hot" - - Data presented support durable antitumor activity - NOVATO, CA / ACCESSWIRE / November 1, 202...
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101 Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor...
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates
Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cells Vaccine candidates hold potential for rapid response to r...
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OT...
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engine...
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly ...
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are...
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine Candidat...
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101
- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with Agen...
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and prev...
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D.
Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic ImmunoEngineeri...